Syantra, Inc., a biotech company focused on changing how cancer is detected, has introduced a new therapeutic division that will create groundbreaking treatments designed to reverse the way cancer affects immune cells and help the body fight cancer more effectively. This move builds on Syantra’s patent-pending Onco-ID platform, which reads signals from the immune system to find signs of active cancer. The company aims to use this technology to develop new therapies that can reprogram the interaction between tumors and the immune system.
Health Technology Insights: New Digestive Breath Device Shows Key Gut Health Benefits
Rob Lozuk, CEO of Syantra, explained that their work in detecting cancer early has naturally led to finding new targets for drugs and treatment methods. He said, “We’ve reached a point where specific targets and methods have been identified, which is really promising for the future of cancer therapy.” Lozuk also pointed out that the platform can be used not only for detection but also for choosing the right patients and tracking their progress, which could improve treatment outcomes.
Olesya Kharenko, PhD, Principal Scientist at Syantra, shared more about the science behind their approach. She explained how tumors teach immune cells to stop fighting cancer. “Our Onco-ID technology lets us recreate a patient’s biological environment in our lab models, helping us find targets that could stop or even reverse this process,” Kharenko explained.
Health Technology Insights: Novotech Backs Approval of Anlotinib Combination for Soft Tissue Sarcoma
In addition to launching this new division, Syantra is continuing its clinical trials for a multi-target whole blood mRNA test. An improved version of the test is expected to be released this fall. The company has also raised more funding to speed up both its research and commercial plans. Lozuk noted the growing interest from doctors and investors, stating that Syantra has filed several patents and expects to file more in the future.
He ended by expressing confidence in the company’s progress, saying, “Every step forward brings us closer to bringing our solutions to the global market and, more importantly, to making early cancer detection and innovative treatments a regular part of everyday healthcare.”
Health Technology Insights: Zydus Reports Positive Phase 2/3 Results for Saroglitazar Trial
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
